Both Short- and Long-Acting D-1/D-2 Dopamine Agonists Induce Less Dyskinesia than l-DOPA in the MPTP-Lesioned Common Marmoset (Callithrix jacchus)-Reference-Cited by-同舟云学术

Both Short- and Long-Acting D-1/D-2 Dopamine Agonists Induce Less Dyskinesia than l-DOPA in the MPTP-Lesioned Common Marmoset (Callithrix jacchus)

Published:2003-01 Issue:1 Volume:179 Page:90-102
ISSN:0014-4886
Container-title:Experimental Neurology
language:en
Short-container-title:Experimental Neurology

Author:

Maratos Eleni C.,Jackson Michael J.,Pearce Ronald K.B.,Cannizzaro Carla,Jenner Peter

Publisher

Elsevier BV

Subject

Developmental Neuroscience,Neurology

Reference88 articles.

1. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature;Ahlskog;Mov. Disord.,2001

2. Locomotor stimulation by l-dopa: Relative importance of noradrenaline receptor activation;Anden;Psychopharmacology,1977

3. Pergolide monotherapy in the treatment of early PD—A randomized, controlled study;Barone;Neurology,1999

4. Chronic treatment with l-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys—correlation with [3H]spiperone binding;Bédard;Brain Res.,1986

5. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys;Blanchet;J. Pharmacol. Exp. Ther.,1995

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liquid Subcutaneous Levodopa-Carbidopa ND0612 Effects on Motor Symptoms in Individuals with Parkinson&#8217;s Disease: A Systematic Review and Meta-Analysis;Advances in Parkinson's Disease;2024

2. Continuous dopaminergic stimulation and the transition to using continuous drug delivery in Parkinson's disease—An introduction;International Review of Movement Disorders;2024

3. Should continuous dopaminergic stimulation be a standard of care in advanced Parkinson’s disease?;Journal of Neural Transmission;2023-11

4. Levodopa-loaded nanoparticles for the treatment of Parkinson's disease;Journal of Controlled Release;2023-08

5. The MPTP-lesioned marmoset model of Parkinson’s disease: proposed efficacy thresholds that may potentially predict successful clinical trial results;Journal of Neural Transmission;2020-08-29